TD Cowen raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps a Buy rating on the shares. The firm said they posted a solid Q4 beat and they expect the company to stay independent but believes its pipeline is being overlooked.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $36 from $30 at Stifel
- Exelixis price target raised to $29 from $25 at Barclays
- Exelixis price target raised to $38 from $37 at Piper Sandler
- Hold Rating on Exelixis Amid Uncertainty in Key Pipeline Asset and Market Opportunities
- Exelixis’s Growth Potential Bolstered by Cabozantinib Expansion and Promising New Drug Developments